Regenerex Pharma Files 2024 Annual Report

TL;DR

Regenerex Pharma filed its 10-K for FY24. Check financials.

AI Summary

Regenerex Pharma, Inc. filed its annual report for the fiscal year ended March 31, 2024. The company, formerly known as Peptide Technologies, Inc. and Eternelle Skincare Products Inc., is incorporated in Nevada and operates in the pharmaceutical preparations sector. Its business and mailing address are located at 5348 Vegas Drive, Suite 177, Las Vegas, NV 89108.

Why It Matters

This filing provides a comprehensive overview of Regenerex Pharma's financial performance and business operations for the past fiscal year, crucial for investors and stakeholders to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This is a standard annual report filing with no immediate red flags or significant new information presented in the provided snippet.

Key Players & Entities

• REGENEREX PHARMA, INC. (company) — Filer
• PEPTIDE TECHNOLOGIES, INC. (company) — Former Company Name
• Eternelle Skincare Products Inc. (company) — Former Company Name
• 20240331 (date) — Fiscal Year End
• 20240624 (date) — Filing Date
• 5348 VEGAS DRIVE, SUITE 177 (address) — Business Address
• LAS VEGAS, NV 89108 (location) — Business Address City, State, Zip
• 305-927-5191 (phone_number) — Business Phone

FAQ

Key Financial Figures

• $0.001 — g) of the Exchange Act: Common Stock, $0.001 par value per share (Title of Class)
• $45,000 — t as of June 11, 2023, in the amount of $45,000, with First Forte Consultancy in the UA
• $22,500 — on of the companies wound care product. $22,500 was paid June 15, 2023, and the balance
• $1.07 b — a three-year period or revenues exceeds $1.07 billion, or the market value of our share
• $700 million — that are held by non-affiliates exceeds $700 million on the last day of the second fiscal qu
• $10,000,000 — of the Company's common stock and up to $10,000,000 in contingent consideration to be paid
• $2,400,000 — million four hundred thousand dollars ($2,400,000) interest-free due August 17, 2024. The

Filing Documents

• ixform10k.htm (10-K) — 590KB
• exhibit31-1.htm (EX-31.1) — 12KB
• exhibit31-2.htm (EX-31.2) — 12KB
• exhibit32-1.htm (EX-32.1) — 4KB
• exhibit32-2.htm (EX-32.2) — 4KB
• regenerexlogo.gif (GRAPHIC) — 6KB
• 0001472375-24-000045.txt ( ) — 3234KB
• rgpx-20240331.xsd (EX-101.SCH) — 30KB
• rgpx-20240331_cal.xml (EX-101.CAL) — 38KB
• rgpx-20240331_def.xml (EX-101.DEF) — 125KB
• rgpx-20240331_lab.xml (EX-101.LAB) — 214KB
• rgpx-20240331_pre.xml (EX-101.PRE) — 185KB
• ixform10k_htm.xml (XML) — 339KB

BUSINESS

BUSINESS 6 ITEM 1A.

RISK FACTORS

RISK FACTORS 10 ITEM 1B. UNRESOLVED STAFF COMMENTS 13 ITEM 1C. CYBERSECURITY 13 ITEM 2.

PROPERTIES

PROPERTIES 13 ITEM 3.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 14 ITEM 4. MINING SAFETY DISCLOSURES 14 PART II ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 15 ITEM 6.

SELECTED FINANCIAL DATA

SELECTED FINANCIAL DATA 15 ITEM 7.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 15 ITEM 7A.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 18 ITEM 8.

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 19 ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 36 ITEM 9A.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 36 ITEM 9B. OTHER INFORMATION 37 PART III ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE 37 ITEM 11.

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 38 ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 39 ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 39 ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES 40 3 PART IV ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES 41

SIGNATURES

SIGNATURES 42 CERTIFICATIONS Exhibit 31 – Management certifications Exhibit 32 – Sarbanes-Oxley Act 4 Special Note Regarding

Forward-Looking Statements

Forward-Looking Statements Some of our statements under "Business," "Properties," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations," the Notes to

Financial Statements and elsewhere in this report constitute "forward-looking

Financial Statements and elsewhere in this report constitute "forward-looking (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934 (the "Exchange Act"). In some cases, forward-looking statements are identified by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "approximates," "predicts," "potential" or "continue" or the negative of such terms and other comparable terminology. Although we believe that the expectations reflected in these forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither we nor anyone else assumes responsibility for the accuracy and completeness of such statements and is under no duty to update any of the forward-looking statements after the date of this report. Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding: our ability to add new customers. the impacts of COVID-19, or other future pandemics on our business, results of operations, financial position and cash flows. the potential benefits of and our ability to maintain our relationships and establish or maintain future collaborations or strategic relationships or obtain additional funding. our marketing capabilities and strategy. our ability to maintain a cost-effective program. our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals. our competitive position, and developments and projections relating to our competitors and our industry. our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and the impact of laws and regulations. All of our forw

forward-looking statements will prove to be correct. An occurrence of, or any

forward-looking statements will prove to be correct. An occurrence of, or any material adverse change in, one or more of the risk factors or risks and uncertainties referred to in this Annual Report on Form 10-K or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the U.S. Securities and Exchange Commission (the "SEC") could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Annual Report on Form 10-K, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Annual Report on Form 10-K that modify or impact any of the

forward-looking statements contained in this Annual Report on Form 10-K will be

forward-looking statements contained in this Annual Report on Form 10-K will be deemed to modify or supersede such statements in this Annual Report on Form 10-K. 5 PART I

BUSINESS

ITEM 1. BUSINESS. Business of Issuer The business of Regenerex Pharma, Inc., (the "Company" or "Regenerex Pharma,"), is to develop and market Woundcare Healing products. The Company has three technologies for different types of wound conditions: The first is for closing chronic wounds, the second is for accelerating closure of acute or surgical wounds, and the third solves the issue on contamination of all types of wounds including the destruction of biofilms . The current product technology provides the Company with a number of complete wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds. These unique products strategically position the Company to enter and capture a high proportionate market share in the U.S. and global markets. Products: 1. Xcellderma OTC - Liquid Bandage Skin Protectant Xcellderma products are sterile wound dressings and are effective for treating diabetic foot ulcers, pressure ulcers, and other chronic wounds. During the last several years, a scientific and medical consensus has emerged that elevated protease levels impede wound healing. QBx the active ingredient down regulates the production of certain proteases and matrix metalloproteases, or MMPs, which are protein enzymes that are proven to impede the healing of a majority of chronic wounds. Approximately 80% of chronic wounds display elevated levels of proteases (including MMPs). 2. Accelerex Sterile Wound Cream - The first commercially available medical device, Accelerex, is for the treatment of a wide variety of chronic and acute wounds. Accelerex is a custom-designed, FDA and CE approved unit-dose, sterile wound dressing impregnated with an ointment containing QBx. Chronic wounds are generally defined as wounds that have not healed after thirty days of consistent clinical treatment, and include diabetic ulcers, burns, pressure ulcers (bedsores), and venous stasis ulcers. The Company's broadly enabling technology

RISK FACTORS

ITEM 1A. RISK FACTORS. The Company will face competition from existing consumer product companies. We are an "emerging growth company" and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our shares of common stock less attractive to investors. We are an "emerging growth company," as defined in the JOBS Act. We will remain an "emerging growth company" for up to five years, following an IPO, or sale of the Company's securities under a registration statement. However, if our non-convertible debt issued within a three-year period or revenues exceeds $1.07 billion, or the market value of our shares of common stock that are held by non-affiliates exceeds $700 million on the last day of the second fiscal quarter of any given fiscal year, we would cease to be an emerging growth company as of the following fiscal year. As an emerging growth company, we are not required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, we have reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and we are exempt from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Additionally, as an emerging growth company, we have elected to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. As such, our financial statements may not be comparable to companies that comply with public company effective dates. We cannot predict if investors will find our shares of common stock less attractive because we may rely on these provisions. If some investors find our shares of common stock less attractive as a result, there may be a less active trading market for our shares and our share price may be more volatile.

View Full Filing

View this 10-K filing on SEC EDGAR